Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07085559 | Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research | recruiting | Early Phase 1 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07066397 | A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL | recruiting | Phase 1 | 12 | TriArm Therapeutics (Taiwan) LimitedINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05929976 | InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort(NICHE) | recruiting | — | 4,900 | Columbia UniversityOTHER | 6 | Jul 22, 2025 | clinicaltrials |
| NCT07059624 | Femoral Arterial Cannulation in Pediatrics | recruiting | N/A | 80 | American University of Beirut Medical CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05703542 | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 24 | Eric Stephen Winer, MDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072494 | CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study | recruiting | Phase 1 / Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04704323 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 18 | Catapult TherapeuticsINDUSTRY | 2 | Jul 17, 2025 | clinicaltrials |
| NCT07059156 | Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL | recruiting | Phase 2 / Phase 3 | 50 | Shanxi Bethune HospitalOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML(PEARL) | recruiting | Phase 2 | 160 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06689917 | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Tongji HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06787144 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants(CML) | recruiting | Phase 1 | 21 | Enliven TherapeuticsINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05618041 | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | recruiting | N/A | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06785324 | Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)(NEOMA ALL) | recruiting | N/A | 20 | University of ChicagoOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT07019766 | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia(NICHE-LGLL) | recruiting | — | 9,999 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07021677 | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"(DARA_T_ALL) | recruiting | Phase 2 | 18 | Tata Memorial CentreOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT04687176 | Frontline Oral Arsenic Trioxide for APL | recruiting | Phase 2 | 100 | The University of Hong KongOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT05219721 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 18 | Chunrui LiOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014449 | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Hangzhou Weben Pharma Co., LtdINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06778187 | Oral-ATO for TP53-mutated Myeloid Malignancies | recruiting | Phase 2 | 30 | The University of Hong KongOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06940960 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | recruiting | Phase 2 | 32 | yuejun LiuOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05541341 | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | recruiting | — | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT07007949 | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia | recruiting | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06119269 | Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase(PHOENICS) | recruiting | — | 100 | University of PisaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06793410 | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06130579 | Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT | recruiting | Phase 2 | 35 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06390306 | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | recruiting | — | 30 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06880354 | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | recruiting | Phase 1 / Phase 2 | 29 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06982274 | Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia(IC-APL2020) | recruiting | Phase 2 | 115 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03937544 | Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL | recruiting | Phase 2 / Phase 3 | 10 | National University of MalaysiaOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06696183 | Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment(SEQUENCE) | recruiting | Phase 2 | 60 | Technische Universität DresdenOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06961669 | Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma(ECAR01) | recruiting | N/A | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT06718244 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT05759793 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT06980155 | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia | recruiting | Early Phase 1 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06869265 | Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia | recruiting | Phase 2 | 56 | Peking University People's HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 / Phase 3 | 126 | Ruijin HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06034561 | Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 50 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06138990 | Pharmacoscopy-guided Clinical Standard-of-care in r/r AML(RAPID-01) | recruiting | Phase 2 | 88 | ETH ZurichOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06890065 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT05062707 | Early Ageing During Therapy in AYA Cancer Patients | recruiting | — | 120 | University Medical Center GroningenOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05124288 | Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways(GITMO-RELAPSE) | recruiting | — | 500 | Ciceri FabioOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 25, 2025source: clinicaltrials